title: High-dose consolidation with local radiation and bone marrow rescue in patients with advanced neuroblastoma.
abstract: Twenty-six children with advanced neuroblastoma were consolidated with cisplatin, BCNU, etoposide, melphalan, 21 Gy of local radiotherapy, and bone marrow rescue in a multicenter study. All patients were over 1 year of age at diagnosis. Twenty-two patients were treated in first complete or partial remission and four in second complete or partial remission. Hematologic rescue was autologous (n = 23), allogeneic (n = 2), or syngeneic (n = 1). Extrahematological toxicity involved primarily the gastrointestinal mucosa. Among five fatal toxicities, three included intestinal hemorrhage. Fourteen patients relapsed after BMT, four of them at the primary site. Seven children survive progression-free after 16-56 months. These results are essentially not different from a single-center study with the same protocol or from other published studies. The value of megatherapy for patients with advanced neuroblastoma or for a subgroup of them can only be established on a larger number of patients than most national trials accrue.
authors.affiliation: Pediatric Department, University of Essen, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Kremens
authors.forename: T
authors.initials: T
authors.lastname: Klingebiel
authors.forename: F
authors.initials: F
authors.lastname: Herrmann
authors.forename: C
authors.initials: C
authors.lastname: Bender-Götze
authors.forename: S
authors.initials: S
authors.lastname: Burdach
authors.forename: W
authors.initials: W
authors.lastname: Ebell
authors.forename: W
authors.initials: W
authors.lastname: Friedrich
authors.forename: E
authors.initials: E
authors.lastname: Koscielniak
authors.forename: H
authors.initials: H
authors.lastname: Schmid
authors.forename: W
authors.initials: W
authors.lastname: Siegert
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002330:Carmustine / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects; D009364:Neoplasm Recurrence, Local; D009447:Neuroblastoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011882:Radiotherapy, High-Energy / Q000009:adverse effects; D012074:Remission Induction; D015996:Survival Rate
chemical_list: D005047:Etoposide; D002945:Cisplatin; D008558:Melphalan; D002330:Carmustine